@article{ref1,
title="Long-acting aripiprazole in the management of violence in treatment nonadherent schizophrenia",
journal="Primary care companion to CNS disorders",
year="2021",
author="Miola, Alessandro and Toffanin, Tommaso and Pavan, Chiara and Comini, Francesco Folena and Salvati, Benedetta and Sambataro, Fabio and Pigato, Giorgio",
volume="23",
number="1",
pages="e2623-e2623",
abstract="The risk of violent behavior is higher in patients with schizophrenia relative to the general population. Violence can be prevented using antipsychotic drugs, with clozapine being the gold standard. Regrettably, the nonadherence rate for oral treatments is very high in schizophrenia, ranging from 40% to 80%, and it is one of the principal factors contributing to violent behavior.1 The introduction of atypical long-acting injectable (LAI) antipsychotics, with faster titration schemes and better tolerability, can improve treatment adherence. Preventing violent activity can reduce criminal behavior in patients with schizophrenia and allow for participation in rehabilitation programs.2 We report on the long-term effectiveness of aripiprazole LAI monotherapy in reducing criminal violent behavior in a treatment nonadherent patient with severe psychosis admitted to an acute ward per court-ordered commitment...<p /> <p>Language: en</p>",
language="en",
issn="2155-7772",
doi="10.4088/PCC.20l02623",
url="http://dx.doi.org/10.4088/PCC.20l02623"
}